Publications
Highlights | 2016 | 2015 | 2014 | 2013 | 2012 | Archived
Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. Green AR, Soria D, Powe DG, Nolan CC, Aleskandarany M, Szász MA, Tokés AM, Ball GR, Garibaldi JM, Rakha EA, Kulka J, Ellis IO. Breast Cancer Res Treat. 2016 Apr 26. [Epub ahead of print].
MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas CC, Madhusudan S, Ellis IO and Rakha EA. British Journal of Cancer. 2016 In Press.
The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. Aleskandarany MA, Agarwal D, Negm OH, Ball G, Elmouna A, Ashankyty I, Nuglozeh E, Fazaludeen MF, Diez-Rodriguez M, Nolan CC, Tighe PJ, Green AR, Ellis IO, Rakha EA. Breast Cancer Res Treat. 2016 Feb 23.
Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma. Laurinavicius A, Plancoulaine B, Rasmusson A, Besusparis J, Augulis R, Meskauskas R, Herlin P, Laurinaviciene A, Abdelhadi Muftah AA, Miligy I, Aleskandarany M, Rakha EA, Green AR, Ellis IO. Virchows Arch. 2016 Jan 27.
Clinical utility of reverse phase protein array for molecular classification of breast cancer. Negm OH, Muftah AA, Aleskandarany MA, Hamed MR, Ahmad DA, Nolan CC, Diez-Rodriguez M, Tighe PJ, Ellis IO, Rakha EA, Green AR. Breast Cancer Res Treat. 2016 Jan;155(1):25-35.
Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. Arora A, Abdel-Fatah TM, Agarwal D, Doherty R, Croteau DL, Moseley PM, Hameed K, Green A, Aleskandarany MA, Rakha EA, Patterson K, Ball G, Chan SY, Ellis IO, Bohr VA, Bryant HE, Madhusudan S. Carcinogenesis. 2016 Jan;37(1):63-71.
Nottingham Prognostic Index Plus (NPI+): Validation of a clinical decision making tool in breast cancer in an independent series. Green AR, Soria D, Stephen J, Powe DG, Nolan CC, Kunkler I, Thomas J, Kerr GR, Jack W, Cameron D, Piper T, Ball GR, Garibaldi JM, Rakha EA, Bartlett JMS, Ellis IO. J Path:Clin Res. 2016 1:32-40.
Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. Alsubhi N, Middleton F, Abdel-Fatah TM, Stephens P, Doherty R, Arora A, Moseley PM, Chan SY, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Martin SG, Curtin NJ, Madhusudan S. Mol Oncol. 2016 Feb;10(2):213-23.
PKCa Attenuates Jagged-1-mediated Notch Signaling in ErbB-2 positive Breast Cancer to Reverse Trastuzumab Resistance. Pandya K, Wyatt D, Gallagher B, Bloodworth JC, Shah D, Baker A, Zlobin A, Pannuti A, Green AR, Ellis IO, Filipovic A, Sagert J, Rana A, Albain KS, Miele L, Denning M, Osipo C. Clin Cancer Res. 2016 Jan 1;22(1):175-86.
HAGE in triple negative breast cancer (TNBC) is a novel prognostic, predictive and actionable biomarker: A Transcriptomic and protein expression analysis. Abdel-Fatah TM, McArdle SE, Agarwal D, Moseley PM, Green AR, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY. Clin Cancer Res. 2016 Feb 15;22(4):905-14.
Construction of tissue microarrays from core needle biopsy - a systematic literature review. Albanghali MA, Green AR, Rakha E, Aleskandarany MA, Nolan C, Ellis IO, Cheung KL. Histopathology. 2016 Feb;68(3):323-32.
Cancer cell associated glycans as targets for immunotherapy. Vankemmelbeke M, Chua JX, Durrant LG. Oncoimmunology. 2015 Jul 15;5(1):e1061177. eCollection 2016. PubMed PMID: 26942075; PubMed Central PMCID: PMC4760334.
Third-generation antibody drug conjugates for cancer therapy - a balancing act. Vankemmelbeke M, Durrant L. Ther Deliv. 2016 Mar;7(3):141-4. doi: 10.4155/tde-2016-0002. PubMed PMID: 26893243.
The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma. Fredholm S, Litvinov IV, Mongan NP, Schiele S, Willerslev-Olsen A, Petersen DL, Krejsgaard T, Sibbesen N, Nastasi C, Bonefeld CM, Persson JL, Straten PT, Andersen MH, Koralov SB, Wasik MM, Geisler C, Sasseville D, Woetmann A, Ødum N. J Invest Dermatol. 2016 Apr;136(4):866-9. doi: 10.1016/j.jid.2015.12.033. Epub 2016 Jan 21. PubMed PMID: 26802931.
Up-regulation of genes involved in the insulin signalling pathway (IGF1, PTEN and IGFBP1) in the endometrium may link polycystic ovarian syndrome and endometrial cancer. Shafiee MN, Seedhouse C, Mongan N, Chapman C, Deen S, Abu J, Atiomo W. Mol Cell Endocrinol. 2016 Mar 5;424:94-101. doi: 10.1016/j.mce.2016.01.019. Epub 2016 Jan 21. PubMed PMID: 26802879.
Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma. Minton DR, Fu L, Mongan NP, Shevchuk MM, Nanus DM, Gudas LJ. Clin Cancer Res. 2016 Jan 18. [Epub ahead of print] PubMed PMID:26783287.
Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Willerslev-Olsen A, Krejsgaard T, Lindahl LM, Litvinov IV, Fredholm S, Petersen DL, Nastasi C, Gniadecki R, Mongan NP, Sasseville D, Wasik MA, Bonefeld CM, Geisler C, Woetmann A, Iversen L, Kilian M, Koralov SB, Odum N. Blood. 2016 Mar 10;127(10):1287-96. doi:10.1182/blood-2015-08-662353. Epub 2016 Jan 5. PubMed PMID: 26738536; PubMed Central PMCID: PMC4786838.
Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. Pallis M, Burrows F, Ryan J, Grundy M, Seedhouse C, Abdul-Aziz A, Montero J, Letai A and Russell N. Oncotarget. 2016 Apr 15. doi: 10.18632/oncotarget.8742. [Epub ahead of print] PMID: 27092880.
Impact of pre-transplantation ([18-F])FDG-PET on survival outcomes following T-cell depleted allogeneic transplantation for Hodgkin lymphoma. Reyal Y, Kayani I, Bloor AJ, Fox CP, Chakraverty R, Sjursen AM, Fielding AK, Ben Taylor M, Bishton MJ, Morris EC, Thomson KJ, Russell N, Mackinnon S and Peggs KS. Biol Blood Marrow Transplant. 2016 Apr 14. pii: S1083-8791(16)30023-4. doi: 10.1016/j.bbmt.2016.03.034. [Epub ahead
of print] PubMed PMID: 27095691.
Incidence and management of hepatic severe veno-occlusive disease in 273 patients in a single centre with defibrotide. Pol RR, Russell N, Das-Gupta E, Watson L, Rachael L and Byrne J. Bone Marrow Transplant. 2016 Apr 25. doi: 10.1038/bmt.2016.99. [Epub ahead of print] PubMed PMID: 27111044.
Relationship between event-free survival and overall survival in acute myeloid leukemia: A report from SWOG, HOVN/SAKK, and MRC/NCRI. Othus M, van Putten W, Lowenberg B, Petersdorf SH, Nand S, Erba H, Appelbaum F, Hills R, Russell N, Burnett A and Estey E. Haematologica. 2016 Mar 24. pii: haematol.2015.138552. [Epub ahead of print] PubMed PMID: 27013652.
Phenotypically Dormant and Immature Leukaemia Cells Display Increased Ribosomal Protein S6 Phosphorylation. Pallis M, Harvey T and Russell N. PLoS One. 2016 Mar 17;11(3):e0151480. doi: 10.1371/journal.pone.0151480. eCollection 2016. PubMed PMID: 26985829; PubMed Central PMCID: PMC4795744.
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control. An analysis from the Lymphoma Working Party Of the EBMT. Robinson SP, Boumendil A, Finel H, Schouten H, Ehninger G, Maertens J, Crawley C, Rambaldi A, Russell N, Anders W, Blaise D, Yakoub-Agha I, Ganser A, Castagna L, Volin L, Cahn JY, Montoto S and Dreger P. Ann Oncol. 2016 Mar 8. pii: mdw124. [Epub ahead of print] PubMed PMID: 26961149.
Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3mg/m2 with 6mg/m2 in the NCRI AML17 trial. Burnett A, Cavenagh J, Russell N, Hills R, Kell J, Jones G, Nielsen OJ, Khwaja A, Thomas I, Clark R. Haematologica. 2016 Feb 26. pii: haematol.2016.141937. [Epub ahead of print] PubMed PMID: 26921360.
Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. Burns DM, Rana S, Martin E, Nagra S, Ward J, Osman H, Bell AI, Moss P, Russell NH, Craddock CF, Fox CP, Chaganti S. Bone Marrow Transplant. 2016 Feb 22. doi: 10.1038/bmt.2016.19. [Epub ahead of print] PubMed PMID: 26901708.
Assessment of Minimal Residual Disease in Standard-Risk AML. Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch DC, Gale RE, Vyas P, Freeman SD, Russell N, Burnett AK, Grimwade D; UK National Cancer Research Institute AML Working Group. N Engl J Med. 2016 Feb 4;374(5):422-33. doi: 10.1056/NEJMoa1507471. Epub 2016 Jan 20. PubMed PMID: 26789727.
Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the UK National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord. Snowden JA, Danby R, Ruggeri A, Marks DI, Hough RE, Pagliuca A, Potter M, Russell N, Craddock C, Clark A, Miller P, Cook G, Gluckman E, Shaw BE, Rocha V. Br J Haematol. 2016 Feb;172(3):478-81. doi: 10.1111/bjh.13913. Epub 2015 Dec 27. PubMed PMID: 26708833.
RECQL4 helicase has oncogenic potential in sporadic breast cancers. Arora A, Abdel-Fatah TMA, Agarwal D, Croteau D, Moseley P, Alsubhi N, Russell R, Green A, Ball G, Aleskandarany MA, Rakha E, Chan SYT, Caldas C, Ellis IO, Wang LL, Bohr V and Madhusudan S. The Journal of Pathology. 2016, Mar;238(4):495-501. doi: 10.1002/path.4681.
Human RecQL4 helicase drives cisplatin resistance by activating YB1-Akt-MDR1 pathway in gastric cancer cells. Mo D, Fang H, Niu K, Liu J, Wu M, Li S1, Aleskandarany AM, Arora A, Lobo DN, Madhusudan S, Balajee AS, Chi Z, Zhao Y. Cancer Research, 2016. Mar 24. pii: canres.2361.2015. [Epub ahead of print].
Camptothecin-induced WRN degradation is a potential sensitivity marker for breast cancer chemotherapy. Shamanna RA, Lu H, Croteau DL, Arora A, Agarwal D, Ball G, Aleskandarany MA, Ellis IO, Madhusudan S and Bohr VA. Oncotarget, 2016. Mar 3. doi: 10.18632/oncotarget.7906.
c-MYC function is associated with specific biological subtypes of breast cancer and confers resistance to endocrine therapy. Green AR, Aleskandarany MA, El-Sheikh S, Nolan CC, Macmillan DR, Caldas C, Madhusudan S, Ellis IO, Rakha EA. British Journal of Cancer, 2016. Mar 8. doi: 10.1038/bjc.2016.46.
Post-transcriptional control of tumor cell autonomous metastatic potential by the CCR4-NOT deadenylase CNOT7. Faraji, F., Hu, Y., Winkler, G.S., Hafner, M., and Hunter, K.W. (2016) PLoS Genetics 12, e1005820.
In vitro anticancer properties and biological evaluation of novel natural alkaloid Jerantinine B. ME Qazzaz, VJ Raja, K-H Lim, T-S Kam, JB Lee, P Gershkovich and TD Bradshaw. Cancer Letters 2016, 370, 185-197.
Fistulopsines A and B, Antiproliferative Septicine-Type Alkaloids from Ficus fistulosa. Veronica A Yap, Mohannad E Qazzaz, Vijay J Raja, Tracey D Bradshaw, Hwei-San Loh, Kae-Shin Sim, Kien-Thai Yong, Yun-Yee Low, Kuan-Hon Lim. Phytochemistry Letters 2016, 15, 136-141.
Enantiopure titanocene complexes – direct evidence for paraptosis in cancer cells. Melchior Cini, Huw Williams, Michael W Fay, Mark S Searle, Simon Woodward and Tracey D Bradshaw. Metallomics, 2016, 8, 286-297.
Highlights of Children with Cancer UK's Workshop on Drug Delivery in Paediatric Brain Tumours. Nailor A, Walker D, Jacques TS, et al. eCancer 2016.
Penetration and intracellular uptake of poly(glycerol-adipate) nanoparticles into three-dimensional brain tumour cell culture models. Meng W, Garnett M, Walker D. Experimental Biology & Medicine 2016; 241(5): 466-77.
Long-term exposure to irinotecan reduces cell migration in glioma cells. Al-Ghafari A, Punjaruk W, Storer L, et al. Journal of Neuro Oncology 2016; 127: 455-62.
Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. Thomas C, Sill M, Ruland V, et al. Neuro Oncology 2016; Jan 28 pii nov322.
Highlights | 2016 | 2015 | 2014 | 2013 | 2012 | Archived